Trial Profile
A randomized, double-blind, placebo-controlled, multicentre, phase II dose-finding study of atacicept given subcutaneously in subjects with rheumatoid arthritis and inadequate response to TNFa antagonist therapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Atacicept (Primary)
- Indications Rheumatoid arthritis
- Focus Pharmacodynamics; Therapeutic Use
- Acronyms AUGUST-I
- Sponsors EMD Serono
- 30 Mar 2011 Results published in the Arthritis and Rheumatism.
- 19 Jun 2010 Primary endpoint results presented at the 11th Annual Congress of the European League Against Rheumatism
- 19 Jun 2010 Primary endpoint 'American College of Rheumatology 20% response criteria' has not been met.